Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers

Autor: Benowitz, Neal, Zhu, AZX, Zhou, Q, Cox, LS, David, SP, Ahluwalia, JS, Benowitz, NL, Tyndale, RF

Publikováno v: Benowitz, Neal; Zhu, AZX; Zhou, Q; Cox, LS; David, SP; Ahluwalia, JS; et al.(2014). Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/5gv7d7nd

Associations between CHRNA5-A3-B4 variants and smoking behaviors exist; however, the association with smoking abstinence is less understood, particularly that among African Americans. In 1,295 African Americans enrolled in two clinical trials, we inv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::e61f48b8c6646b3447f9e62bf1aec9f1
http://www.escholarship.org/uc/item/5gv7d7nd

Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes

Autor: Zhu, AZX, Zhou, Q, Cox, LS, Ahluwalia, JS, Benowitz, NL, Tyndale, RF

Publikováno v: Zhu, AZX; Zhou, Q; Cox, LS; Ahluwalia, JS; Benowitz, NL; & Tyndale, RF. (2014). Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metabolism and Disposition, 42(11), 1971-1977. doi: 10.1124/dmd.114.060285. UCSF: Retrieved from: http://www.escholarship.org/uc/item/6qm655sb

Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics. Bupropion is used clinically to treat depression and to promote smoking cessation. It is metabolized by CYP2B6 to its active metabolite hydroxybupropion, yet al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::b4bd7e41b80eb5a67a7d4f4fff163a40
http://www.escholarship.org/uc/item/6qm655sb

Variation in Trans-3′-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake

Autor: Benowitz, Neal, Zhu, AZX, Zhou, Q, Cox, LS, Ahluwalia, JS, Benowitz, NL, Tyndale, RF

Publikováno v: Benowitz, Neal; Zhu, AZX; Zhou, Q; Cox, LS; Ahluwalia, JS; Benowitz, NL; et al.(2013). Variation in Trans-3′-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/69j3x6rq

Background: CYP2A6 metabolizes nicotine to its primary metabolite cotinine and also mediates the metabolism of cotinine to trans-3′-hydroxycotinine (3HC). The ratio of 3HC to cotinine (the "nicotine metabolite ratio", NMR) is an in vivo marker for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::056b4de34810f6be7de8b218439dd81e
http://www.escholarship.org/uc/item/69j3x6rq

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema.

Autor: Sexton D; Takeda Development Center Americas, Inc., Lexington, MA, USA., Nguyen HQ; Takeda Development Center Americas, Inc., Lexington, MA, USA., Juethner S; Takeda Development Center Americas, Inc., Lexington, MA, USA., Luo H; RES Group Inc., Needham, MA, USA., Zhang Z; RES Group Inc., Needham, MA, USA., Jasper P; RES Group Inc., Needham, MA, USA., Zhu AZX; Takeda Development Center Americas, Inc., Lexington, MA, USA. andy.zhu@takeda.com.; Preclinical and Translational Science Department, Takeda Pharmaceutical Company Limited, 35 Landsdowne Street, Cambridge, MA, 02139, USA. andy.zhu@takeda.com.

Publikováno v: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Dec; Vol. 51 (6), pp. 721-734. Date of Electronic Publication: 2024 May 11.

Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis.

Autor: Chenoweth MJ; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Peng AR; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Zhu AZX; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Cox LS; Department of Population Health, University of Kansas School of Medicine, Kansas City, KS, USA., Nollen NL; Department of Population Health, University of Kansas School of Medicine, Kansas City, KS, USA., Ahluwalia JS; Departments of Behavioral and Social Sciences and Medicine, Brown University, Providence, RI, USA., Benowitz NL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Knight J; Data Science Institute, Lancaster University Medical School, Lancaster, UK.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Swardfager W; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Tyndale RF; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Publikováno v: Addiction (Abingdon, England) [Addiction] 2022 Jun; Vol. 117 (6), pp. 1715-1724. Date of Electronic Publication: 2021 Dec 03.